Programme
Nairobi, Kenya, June 23, 2009

DNDi’s
2nd Stakeholders’ Meeting
and
3rd African Meeting

Building regional partnerships to deliver Best science for the most neglected
# Meeting Timeline

**Morning Session 1 - DNDi Strategy**  
**Chairs:** Marcel Tanner, MPH, PhD, and Monique Wasunna, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00 - 9.15</td>
<td>Welcoming Remarks</td>
<td>Solomon Mpoke, PhD, Acting Director of KEMRI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Marcel Tanner, MPH, PhD, Director, Swiss Tropical Institute; Chair, DNDi Board</td>
</tr>
<tr>
<td>9.35 - 10.20</td>
<td><strong>DNDi Update: Global Partnership</strong></td>
<td>Bernard Pecoul, MPH, MD, Executive Director, DNDi &amp; Shing Chang, PhD, R&amp;D Director, DNDi</td>
</tr>
<tr>
<td></td>
<td><strong>Addressing Needs of Most Neglected - From Research Through Access</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Regional Update of DNDi Africa and Research Platforms</strong></td>
<td>Monique Wasunna, MD, PhD, Assistant Director, Research, KEMRI; Head, DNDi Africa</td>
</tr>
<tr>
<td>10.20 - 10.45</td>
<td>Audience Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>10.45 - 11.15</td>
<td>Tea Break</td>
<td></td>
</tr>
</tbody>
</table>

**Morning Session 2 - Delivering Innovation to Patients:**  
**On-the-Ground Access Challenges**  
**Chairs:** Constantin Miaka Bilenge, MD, and Gill Samuels, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.15 - 11.30</td>
<td><strong>Human African Trypanosomiasis:</strong> Conducting quality trials in resource-poor settings</td>
<td>Wilfried Mutombo, MD, NECT Local Investigator, PNLTHA Kasaï Oriental (DRC)</td>
</tr>
<tr>
<td>11.30 - 11.45</td>
<td><strong>Leishmaniasis East African Platform (LEAP): Preparing the field for implementation</strong></td>
<td>Ahmed Musa Mudawi, MD, Institute of Endemic Diseases, University of Khartoum (Sudan)</td>
</tr>
<tr>
<td>11.45 - 12.00</td>
<td><strong>Improving Access to ACTs via Home-Based Management?</strong></td>
<td>Ambrose Talisuna, MBChB, MSc, PhD, MMV (Uganda)</td>
</tr>
<tr>
<td>12.00 - 12.30</td>
<td>Panel discussion:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Fr. Bompart, sanofi-aventis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• C. Fournier, MSF International</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• J. Jannin, WHO</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• P. Tindana, Navrongo Health Research Centre (Ghana)</td>
<td></td>
</tr>
<tr>
<td>12.30 - 13.00</td>
<td>General audience discussion</td>
<td></td>
</tr>
<tr>
<td>13.00 - 14.30</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>
Meeting Timeline (continued)

Afternoon Session 3 – Enabling a Favorable R&D Environment in Africa
Chairs: Wilfred Mbacham, PhD, and Ben Shapiro, MD

14.30 – 14.45 How innovative mechanisms contribute to scaling up access to treatments and establishing new mechanisms to boost innovation for neglected diseases
  Jorge Bermudez, MD, Executive Secretary, UNITAID

14.45 – 15.00 Role of a donor in strengthening research capacity in disease-endemic countries and ensuring sustainable funding for most neglected diseases
  Jo Mulligan, Health Adviser, DFID (UK)

15.00 – 15.15 Adapting approval mechanisms to new NTD drugs
  Javier Guzman, MBBS, MSc, Director of Research, The George Institute, on behalf of Mary Moran, MD, Director, Health Policy Division, The George Institute (Australia)

15.15 – 15.30 Strengthening regulatory capacity in Africa
  David Okello, WHO Representative in Kenya, on behalf of Precious Matsoso, Director, Public Health Innovation and Intellectual Property, WHO (South Africa)

15.30 – 16.00 Panel discussion:
  • Charles Mazinda (Sudan)
  • George W. Baguma (Uganda)
  • J. Amuasi (Ghana)
  • T. Hailu (Ethiopia)

16.00 – 16.30 General audience discussion

16.30 – 17.00 Tea break

Afternoon Session 4 – Keynote Address
Chaired by Marcel Tanner

17.00 – 17.40 Keynote addresses
  Ogobara Doumbo, MD, Director, Malaria Research and Training Center (Mali)
  Carlos Morel, MD, DSc, Director, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation, Fiocruz; member, DNDi Board (Brazil)
  William Lore, MD, MRCP, FCRP, Editor-in-Chief, The East African Medical Journal (Kenya)

17.40 – 18.00 ‘Success Stories’ Project / Partner of the Year
  Khirana Bhatt, MD, MRCP, Member of DNDi Scientific Advisory Committee

18.00 – 18.15 Concluding Remarks
  Marcel Tanner
Morning Session 1 - DNDi Strategy
Chairs: Marcel Tanner, MPH, PhD, and Monique Wasunna, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00 - 9.15</td>
<td>Welcoming Remarks</td>
<td>Solomon Mpoke, PhD, Acting Director of KEMRI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Marcel Tanner, MPH, PhD, Director, Swiss Tropical Institute; Chair, DNDi Board</td>
</tr>
<tr>
<td>9.35 - 10.20</td>
<td>DNDi Update: Global Partnership Addressing Needs of Most Neglected - From Research Through Access</td>
<td>Bernard Pecoul, MPH, MD, Executive Director, DNDi &amp; Shing Chang, PhD, R&amp;D Director, DNDi</td>
</tr>
<tr>
<td></td>
<td>Regional Update of DNDi Africa and Research Platforms</td>
<td>Monique Wasunna, MD, PhD, Assistant Director, Research, KEMRI; Head, DNDi Africa</td>
</tr>
<tr>
<td>10.20 - 10.45</td>
<td>Audience Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>10.45 - 11.15</td>
<td>Tea Break</td>
<td></td>
</tr>
</tbody>
</table>

CHAIRS

Marcel Tanner, MPH, PhD. Director, Swiss Tropical Institute (STI) and Chair of DNDi Board of Directors (Switzerland)

Marcel Tanner obtained a PhD on medical biology from the University of Basel and a MPH from the University of London. He is Director of the Swiss Tropical Institute and Professor of Epidemiology and Medical Parasitology at the University of Basel and at the Federal Institute of Technology. Since 1977, his research ranges from basic research on the cell biology and immunology on malaria, schistosomiasis, trypanosomiasis and filariasis to epidemiological and public health research on risk assessment, vulnerability, health impact and district health planning. His research, teaching and health planning expertise are based on substantial long term experience from working in rural and urban areas in Africa (mainly Tanzania, Chad, Burkina Faso and Côte d'Ivoire) and Asia (China, Thailand, Laos). He was co-investigator and coordinator of the first African malaria vaccine trial in 1992 and participated since then in several major intervention trials on malaria (iron supplementation, intermittent preventive treatment) and schistosomiasis. He has published over 400 original research papers as well as numerous book chapters and reviews. He also acts as advisor on communicable diseases research and control, health systems strengthening and capacity building in various national and international agencies/bodies and in boards/committees such as e.g. WHO/STAC-TDR, DNDi, CHNRI, INCLEN-Trust. Marcel is Chair of DNDi’s Board of Directors since July 2007.
Monique Wasunna, MD, PhD. Assistant Director, KEMRI; Head of DNDi Africa (Kenya)

Dr. Monique Wasunna is the acting Director of the Kenya Medical Research Institute (KEMRI), a Government parastatal charged with the mandate of carrying out biomedical research in Kenya. KEMRI, a founding partner of DNDi, hosts the Africa liaison office in Nairobi, Kenya, which Dr. Wasunna heads. She is a physician by training and an infectious disease specialist. Dr. Wasunna is a founding member and a former chair of the Leishmaniasis East Africa Platform (LEAP). Her research interests have been primarily focused on clinical trials in Visceral Leishmaniasis (VL), as well as malaria and HIV. In addition to DNDi and LEAP, she collaborates with WHO/TDR. Dr. Wasunna was appointed a member of the International Bioethics Committee (IBC) of UNESCO (2008-2011) by the Director General, UNESCO, and is a member of the IBC Working Group on Social Responsability and Health.

SPEAKERS

Solomon Mpoke. PhD. Acting Director of Kenya Medical Research Institute (KEMRI) (Kenya)

Currently the Acting Director of KEMRI, Solomon Mpoke is also Chief Research Officer & Head of KEMRI Graduate School of Health Sciences, as well as serving as a honorary lecturer at the University of Nairobi Institute of Tropical and Infectious Diseases. His research has focused in immunology of HIV; lymphocyte dynamics and biological response modifiers in HIV disease; regulated cell death (apoptosis) in HIV pathogenesis; assessment of cell surface surrogate markers with prognostic significance in HIV infection; in-depth understanding of immune correlates in HIV infection.

Bernard Pécoul. MPH, MD. Executive Director, DNDi

Dr. Pécoul has led DNDi since its founding in 2003. DNDi and its partners have built the largest and most robust R&D portfolio ever for three of the most neglected diseases (leishmaniasis, human African trypanosomiasis, and Chagas disease), and launched ASAQ and ASMQ, two low-cost, non-patented antimalarial combinations. He played a key role in the formation of DNDi as part of the Access to Essential Medicines Campaign of Médecins Sans Frontières (MSF). Prior to his involvement with the campaign, Dr. Pécoul was the Executive Director of MSF-France, a co-founder of Epicentre, and a MSF field physician in Africa, Latin America, and Asia. Bernard Pécoul obtained his MD from the University of Clermont Ferrand in France and his MPH from Tulane University in the USA.

Shing Chang. PhD. Research & Development Director, DNDi

Dr. Chang is responsible for building DNDi’s project portfolio and advancing the discovery and development of new treatments for neglected diseases. Prior to joining DNDi in October 2007, Dr. Chang was a pharmaceutical industry executive: serving as Senior Vice President, Drug Discovery and Chief Scientific Officer at ICOS Corporation; holding various management positions at Abbott Laboratories in diagnostics and pharmaceutical research, including seven years as Divisional Vice President, Infectious Disease Research, in the global pharmaceutical research and development division; and rising to Vice President, Preclinical and Development at Cetus Corporation after joining initially as one of its first molecular biologists. Dr. Chang completed postdoctoral fellowships at the University of Wisconsin and Stanford University. He received his PhD in Molecular Biology and Biochemistry from the University of California, Santa Barbara, and his BS in Biology from Fu-Jen Catholic University in Taiwan.
# Morning Session 2 - Delivering Innovation to Patients: On-the-Ground Access Challenges

**Chairs: Constantin Miaka Bilenge, MD, and Gill Samuels, PhD**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.15</td>
<td>Human African Trypanosomiasis: Conducting quality trials in resource-poor settings</td>
<td>Wilfried Mutombo, MD, NECT Local Investigator, PNLTHA Kasai Oriental (DRC)</td>
</tr>
<tr>
<td>11.30</td>
<td>Leishmaniasis East African Platform (LEAP): Preparing the field for implementation</td>
<td>Ahmed Musa Mudawi, MD, Institute of Endemic Diseases, University of Khartoum (Sudan)</td>
</tr>
<tr>
<td>11.45</td>
<td>Improving Access to ACTs via Home-Based Management?</td>
<td>Ambrose Talisuna, MBChB, MSc, PhD, MMV (Uganda)</td>
</tr>
<tr>
<td>12.00</td>
<td>Panel discussion:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Fr. Bompart, sanofi-aventis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• C. Fournier, MSF International</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• J. Jannin, WHO</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• P. Tindana, Navrongo Health Research Centre (Ghana)</td>
<td></td>
</tr>
<tr>
<td>12.30</td>
<td>General audience discussion</td>
<td></td>
</tr>
<tr>
<td>13.00</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>

## Chairs

**Constantin Miaka Bilenge. MD. Secretary General, Ministry of Health, Democratic Republic of Congo and Special Advisor, National HAT Control Programme, Kinshasa (Democratic Republic of the Congo)**

Dr. Bilenge is a medical doctor with decades of experience in study, treatment, and advocacy for greater attention to neglected diseases such as malaria and sleeping sickness. He has also been engaged in conducting clinical research on therapeutics for sleeping sickness. Currently serving as Secretary General in the Ministry of Health of the Democratic Republic of the Congo, Dr. Bilenge also acts as Special Advisor to the National HAT Control Programme. Dr. Bilenge has served on the Board of the Roll Back Malaria Partnership and is a member of MotherNewBorNet.

**Gill Samuels. PhD. Chair of the Foundation Council of the Global Forum for Health Research. Member, DNDi Board of Directors**

Gill Samuels, a physiologist and neuropharmacologist by training, joins the DNDi Board of Directors in 2008 after a distinguished career as a scientist and pharmaceutical executive. She most recently served as Pfizer’s Executive Director of Science Policy and Scientific Affairs for Europe. Prior to her position in Science Policy, Dr. Samuels directed Pfizer’s Cardiovascular Biology, contributing to the discovery of several new medicines. Dr. Samuels currently acts as Chair of the Foundation Council of the Global Forum for Health Research.
SPEAKERS

Wilfried Mutombo. MD. NECT Local Investigator, PNLTHA Kasai Oriental (DRC)

Wilfried Mutombo acts as the Principal Site Investigator at Dipumba Hospital in Democratic Republic of the Congo for both the concluded NECT Phase III study as well as the ongoing NECT-FIELD study. Since receiving his medical degree from the University of Mbuji Mayi, Dr. Mutombo has been engaged in treating patients and conducting clinical research on diseases affecting the local population, including human African trypanosomiasis and HIV/AIDS. He has also participated within regional vaccination campaigns.

Ahmed Musa Mudawi. MD. Department of Immunology and Clinical Pathology, Institute of Endemic Diseases, University of Khartoum (Sudan)

Dr. Ahmed Musa Musa, assistant Professor at the Institute of Endemic Diseases (IEND), University of Khartoum, is a specialist in immunology, tropical medicine practice and research. He has headed the leishmaniasis research group of the IEND since 2004. Dr. Musa is an expert on post kala-azar dermal leishmaniasis (PKDL), leishmaniasis immunotherapy, and therapeutic leishmaniasis vaccine studies. He has led the IEND team to Western Sudan (Darfur), Southern Sudan (Bantu) and Eastern Sudan (Kassala), is principal investigator for DNDi at the treatment centres in Kassab and Dooka, and advises the Gedaref State Ministry of Health and DNDi. Dr. Musa is also a WHO/TDR temporary advisor for clinical trials. Dr. Musa is the current chair of the Leishmaniasis East Africa Platform (LEAP).

Ambrose Talisuna. MBChB, MSc, PhD. Medicines for Malaria Venture (Uganda)

Country Representative in Kampala, Ambrose joins MMV as a Member of the Access and Delivery team. He is formerly Assistant Commissioner at the Epidemiology Surveillance Division, Ministry of Health in Kampala, Uganda. Ambrose is a physician and epidemiologist by training and has worked in the area of tropical disease surveillance and control for over 10 years. Apart from an MBChB, Ambrose holds an MSc in Epidemiology from the London School of Hygiene and Tropical Medicine and a PhD from the University of Antwerp in Belgium. He has published over 35 peer-reviewed papers in well-known scientific journals and has been an advisor to a wide array of international organizations. Ambrose is currently a member of the international Ethical Review Board of Médecins Sans Frontières, a consultant to the WHO and a member of the Global Fund TRP.
PANELISTS

François Bompart. MD. Director of the Impact Malaria program, Sanofi Aventis (France)

François Bompart is currently Vice-President of the Access to Medicines department, and Director of the Impact Malaria program at Sanofi Aventis in Paris (France). He graduated from Angers Medical School (France) in 1984, and then trained in clinical pharmacology at University College London (UK) and at Hôpital Cochin in Paris (France). In 1988, he joined Smith Kline and French medical department in Paris, as Director for gastroenterology and vaccines. From 1991 to 1997, he held various positions at Rhône Poulenc Rorer in the clinical development of antibiotics, including a 5-year assignment in the USA. In 1998, he joined the vaccines division of the Rhône Poulenc group, Pasteur Mérieux Connaught (now Sanofi Pasteur) in Lyon (France) where he held successively the positions of Vice-President, Medical Affairs for the International area (1998-2001) and Vice-President, Global Medical Affairs (2001-2005). He joined Sanofi Aventis’ Access to Medicines department in January 2006. Sanofi Aventis’ Access to Medicines department’s mission is to break down the barriers that impede access to treatments for patients in developing and emerging countries, for specific diseases in which Sanofi Aventis has particular expertise: malaria, tuberculosis, sleeping sickness, epilepsy, mental health, as well as access to vaccines.

Christophe Fournier. MD. President, Médecins Sans Frontières International (MSF). Member, DNDi Board of Directors

Christophe Fournier, in addition to serving on DNDi’s Board of Directors, is President of the Médecins Sans Frontières/Doctors Without Borders (MSF) Movement. Previously, he held the position of Operations Manager at MSF, based in the United States. In this capacity, he directly managed field programs from a headquarters level for operations in Guatemala, Haiti, Nigeria, Sudan, Cambodia, Myanmar and Thailand. In addition, Dr. Fournier has also served as a medical doctor or head of mission for MSF field projects in Burundi, Uganda, Honduras, and Chile, and has conducted several emergency exploratory missions in Mexico and Venezuela. Dr. Fournier received his M.D. from the University of Clermont-Ferrand in France, and also holds a degree in Tropical Medicine, Epidemiology and Biostatistics.

Jean Jannin. MD. MPH. Coordinator, Innovative & Intensified Disease Management, Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva (Switzerland)

As Coordinator of the Innovative & Intensified Disease Management Unit at WHO, Dr. Jannin, among other duties, is responsible for the control programmes against human African trypanosomiasis, leishmaniasis, Chagas disease, Buruli Ulcer, and Yaws. In addition to his role at WHO, Dr. Jannin is currently Inspector General of Public Health at the French Ministry of Health. Prior to joining WHO in 1995, Dr. Jannin worked for over a decade in preventive medicine in Africa treating tuberculosis, leprosy, schistosomiasis, and sleeping sickness. Notably, he was the head of the sleeping sickness national program in Congo. Dr Jannin has both degrees in medicine and public health, and is a graduate of the French National School of Public Health and the Institute of Political Sciences.
Paulina Tindana, Navrongo Health Research Centre, Ghana. Member of DNDi Board of Directors as Patient Representative

Paulina Tindana is a bioethicist with the GCGH ESC Program, and lead author of GCGH: Community Engagement in Research in Developing Countries. Paulina Tindana has a Bachelors degree in English and Linguistics from the University of Ghana. She is currently the IRB Administrator of the Navrongo Health Research Center in Navrongo, Ghana. She has participated in international ethics workshops including the African Malaria Vaccine Testing Network Workshop on Ethics in Kisumu, Kenya, April, 2001 and the PRIM&R workshop in San Diego in October, 2000, and in Boston in November, 2001. She has observed IRBs at the U.S. NIH and the U.S. Navy in Bethesda. Ms. Tindana is conducting a research project for her practicum to explore the motivations for research participation among residents living in the district served by the Navrongo Health Research Center in Ghana. She also has been developing training materials for seminars on research ethics to be delivered in various research institutions in Ghana as well as developing a more comprehensive operations manual for the institutional review board at the Navrongo Health Research Center.
Afternoon Session 3 – Enabling a Favorable R&D Environment in Africa

Chairs: Wilfred Mbacham, PhD, and Ben Shapiro, MD

14.30 – 14.45  How innovative mechanisms contribute to scaling up access to treatments and establishing new mechanisms to boost innovation for neglected diseases  
Jorge Bermudez, MD, Executive Secretary, UNITAID

14.45 – 15.00  Role of a donor in strengthening research capacity in disease-endemic countries and ensuring sustainable funding for most neglected diseases  
Jo Mulligan, Health Adviser, DFID (UK)

15.00 – 15.15  Adapting approval mechanisms to new NTD drugs  
Javier Guzman, MBBS, MSc, Director of Research, The George Institute, on behalf of Mary Moran, MD, Director, Health Policy Division, The George Institute (Australia)

15.15 – 15.30  Strengthening regulatory capacity in Africa  
David Okello, WHO Representative in Kenya, on behalf of Precious Matsoso, Director, Public Health Innovation and Intellectual Property, WHO (South Africa)

15.30 – 16.00  Panel discussion:  
- Charles Mazinda (Sudan)  
- George W. Baguma (Uganda)  
- J. Amuasi (Ghana)  
- T. Hailu (Ethiopia)

16.00 – 16.30  General audience discussion

16.30 – 17.00  Tea break

CHAIRS

Wilfred Mbacham. PhD, Associate Professor, Public Health and Biotechnology, The Biotechnology Centre, University of Yaounde and Local MI M Organizing Secretariat (Cameroon)

Wilfred Fon Mbacham is the Founder and President of the Fobang Foundation. He is Assistant Professor in the Biochemistry Department and Researcher at the Biotechnology Center of the University of Yaounde I, Cameroon. He earned a Bachelors in Zoology and continued with graduate studies in Biochemistry leading to a Doctorat de Specialite, in 1989, from the University of Yaounde, Cameroon. He also holds a Doctor of Science in Tropical Public Health (1997) from Harvard University. In 1994, he was honored as a Schweitzer Fellow, then successively went on to become the Student Chair (1995) and Program Coordinator (1996) of the Boston Schweitzer Urban Fellows Program. Wilfred is Editorial Board member of the Harvard Journal of Minority Public Health. He has since returned to Cameroon where he is the Founding President of The Fobang Foundation, a nongovernmental organization in pursuit of the encouragement of Science & Discovery and the Provision of Public Health Services to the disenfranchised through harmonized sustainable development initiatives. He volunteers as technical director on the American Embassy AIDS Task Force in Cameroon and is a public health consultant with local international agencies. He continues to research on the nation wide molecular epidemiology of resistance markers in Malaria funded in part by the International Atomic Energy Agency, Vienna, Austria and the World Health Organization, Geneva, Switzerland.
Bennett Shapiro. MD. PureTech Ventures, formerly with Merck & Co., Member, DNDi Board of Directors (USA)

Dr. Shapiro was formerly Executive Vice President, Worldwide Licensing and External Research at Merck Research laboratories. Previously at Merck, he held the position of Executive Vice President, Worldwide Basic Research. Prior to entering the pharmaceutical industry, Dr. Shapiro was Professor and Chairman of the Department of Biochemistry at the University of Washington. He also held the position of Chief, Section on Cellular Differentiation in the Laboratory of Biochemistry at the US National Institutes of Health (NIH) and was a visiting scientist at the Institut Pasteur earlier in his career. Dr. Shapiro presently serves on Boards of several biotechnology companies and non-profit organizations. Dr. Shapiro received his MD from Jefferson Medical College in the USA.

SPEAKERS

Jorge Bermudez. MD. Executive Secretary, UNITAID

Dr Jorge Bermudez was appointed as UNITAID’s Executive Secretary in March 2007 and came into Office in July 2007. A graduate doctor, Dr Bermudez has a Master’s degree in Tropical Medicine and a Doctorate in Public Health. Previous experience includes being Unit Chief for Essential Medicines, Vaccines and Health Technologies at the Pan American Health Organization in Washington and Director of the Brazilian National School of Public Health. He played a leading role in the 2005 Second round of Price Negotiations in Latin America for antiretrovirals and diagnosis/monitoring reagents achieving price reductions which have become reference prices in a variety of countries and for the PAHO Strategic Fund supplies.

Jo Mulligan, Health Adviser, DFID (UK)

Jo Mulligan is a Health Adviser in the UK Department for International Development's Research division. DFID works directly in over 150 countries worldwide, with a budget of £5.3 billion in 2007/08. Prior to DFID, Jo was Lecturer in health economics and policy at the London School of Hygiene and Tropical Medicine where her main research interests were the economics of malaria, health system performance and public private partnerships. DFID has been the first government donor to Product Development Partnerships (PDPs) in 1997 to IAVI and is currently funder of 5 PDPs (DNDi, IAVI, MMV, IPM and TB Drug Alliance).

Mary Moran. MBBS (Bachelor of Medicine, Bachelor of Surgery, Hons). Grad Dip, FAT, FRSM. Director, Health Policy Division, The George Institute (Australia)

Dr Mary Moran trained as a medical doctor, working for 13 years in Emergency Medicine at teaching and affiliated hospitals in Australia. A post-graduate degree in international relations and politics at University of NSW and Monash University led her into a career as a diplomat with the Australian Department of Foreign Affairs & Trade, including a posting to London where she focused on climate change negotiations and international trade. Mary subsequently worked for Médecins Sans Frontières, initially as Director of the Access to Essential Medicines Campaign in Australia and later as a Europe-based advocate on a range of issues relating to access to medicines for neglected patients. In 2004, she founded a health policy unit at the London School of Economics, and subsequently transferred the Unit to The George Institute, Sydney, in 2006, where she continues as Director. Mary has participated in numerous Workings Groups and Committees examining neglected diseases, including the WHO Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH); the Rockefeller Health Innovation Systems in Developing Countries Working Group; the OECD Expert Working Group in Innovative Financing; and, currently, the WHO Expert Working Group in R&D Financing. She is or has been an adviser to the European Commission, EDCTP and Wellcome Trust, and is an Honorary Senior Lecturer at the London School of Hygiene and Tropical Medicine.
David Okello, WHO Representative in Kenya, on behalf of Malebona Precious Matsoso. Director, Public Health Innovation and Intellectual Property (PHI), World Health Organization (WHO)

Malebona Precious Matsoso has been the Director of the Department of Technical Cooperation for Essential Drugs and Traditional Medicines, and has been appointed in this position for two years and nine months. Prior to this she has been the Registrar of Medicines of the National Drug Regulatory Authority in South Africa, the Medicines Control Council. She has been a senior official in the South African Government for nine and a half years and also served as Secretariat of the Southern African Development Community (SADC) harmonization initiative and has coordinated related activities for the region for effective regulation of medicines in the region. She has served in various bodies including Medicines Control Council, which she headed for 7 years, responsible for overseeing 10 technical committees. She has been a member of the National Research Ethics Council in South Africa and has produced over 40 technical guidelines for the medicines regulatory authority in South Africa. She directed the development of the National Drug Policy and the Essential Drugs Programme for South Africa.

PANELISTS

Charles Stanley Mazinda (Sudan)

Sudanese born in Yambio, South Sudan in 1969. A Medical Laboratory technologist (parasitology and medical entomology). Graduated in 1996 from Omdurman Ahlia University, faculty of medical laboratory sciences. Attended basic school in South Sudan and completed high school in Comboni College, a missionary school in Khartoum. Currently Lab Supervisor for the ASAQ Studies in Liberia and Deputy Director for Lab services in South Sudan. Have 11 years of work experience with MSF as national and expatriate Lab Supervisor. Worked with MSF-Holland as National Lab Supervisor in the Kala-Azar project in Gedaref for 5 years. Have been working as expatriate Lab Supervisor with MSF-Holland since 2003. Have worked in Myanmar, India, Uganda, Somalia, and Liberia.

George W. Baguma. BSc. MSc. Marketing Director, Quality Chemical Industries LTD (Uganda)

George Baguma has over 15 years of experience in large business groups and multinationals in Uganda, particularly in sales and marketing. He has successfully co-founded two companies and steered them to growth and prosperity. In his current roles at Quality Chemical Industries Ltd., Mr. Baguma is responsible for planning, marketing, and distribution of products, promoting Quality Chemical Industries Ltd.’s corporate image, and the company’s strategic division. Prior to co-founding Quality Chemical Industries Ltd., Mr. Baguma worked in Uganda’s Ministry of Agriculture in the following roles: Principal Research Officer and Deputy Commissioner, Directorate of Animal Resources. He has also held positions in the Co-ordination Office for the Control of Trypanosomiasis in Uganda, Component Manager of the World Bank Livestock Development Program, and FAO Consultant for Disease Control in Tanzania and Zimbabwe. Mr. Baguma has a BSc honors degree from the Makerere University (Uganda) and an MSc from the Imperial College of Science Technology and Medicine from the University of London (UK).
John H. Amuasi. BSc, MBChB, MPH. Acting Head of R&D Unit, Komfo Anokye Teaching Hospital (Ghana)

John Amuasi is a physician by training who envisions contributing significantly to the betterment of Africa and the developing world through the formulation and implementation of appropriate health policies and the application of good management practices. He holds a BSc in human biology and an MBChB both from the School of Medical Sciences, Kwame Nkrumah University of Science and Technology-Kumasi, Ghana. John worked as a Medical Officer at the Komfo-Anokye Teaching Hospital, Kumasi, Ghana and will is currently the Head of R&D Department. He pursued an MPH in Health Policy and Administration at the University of Minnesota.

Tizita Hailu. MD. Chief Medical Officer. Federal Ministry of Health (Ethiopia)

Dr. Tizita Hailu, currently a chief medical officer at the Federal Ministry of Health (FMOH) in Ethiopia, is the Director of Pastoralist Health Promotion and Disease Prevention Directorate. Her career as a medical officer in the Ministry began when she worked as an expert in non-communicable diseases prevention and control. Later, she played an important role in the health sector reform program of the FMOH - Ethiopia. Dr. T. Hailu studied medicine at the Faculty of Medicine, Addis Ababa University. Prior to her assignment at the FMOH, she was a general practitioner in Jimma University Hospital, southwestern Ethiopia.
# Afternoon Session 4 – Keynote Address

## Chaired by Marcel Tanner

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.00 – 17.40</td>
<td><strong>Keynote addresses</strong></td>
<td><strong>Ogobara Doumbo</strong>, Director, Malaria Research and Training Center (Mali)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Carlos Morel</strong>, Director, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation, Fiocruz; member, DNDi Board (Brazil)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Bill Lore</strong>, Editor-in-Chief, The East African Medical Journal (Kenya)</td>
</tr>
<tr>
<td>17.40 – 18.00</td>
<td><strong>‘Success Stories’ Project / Partner of the Year</strong></td>
<td><strong>Khirana Bhatt</strong>, Member of DNDi Scientific Advisory Committee</td>
</tr>
<tr>
<td>18.00 – 18.15</td>
<td><strong>Concluding Remarks</strong></td>
<td><strong>Marcel Tanner</strong></td>
</tr>
</tbody>
</table>

## CHAIR

Marcel Tanner. PhD. MPH. Director, Swiss Tropical Institute (STI). Chair, DNDi Board

## SPEAKERS

**Ogobara Doumbo. MD. Director, Malaria Research and training Center (Mali)**

[Dr. Ogobara Doumbo](#)

Dr. Ogobara Doumbo is a current Member of Science and Health Advisory Board at Malaria No More. Dr. Ogobara Doumbo is the Director of the Malaria Research and Training Center and Chair of the Department of Epidemiology of Parasitic Diseases at the University of Mali. From 1996 to 2001, he directed the Mali-Tulane Tropical Medical Research Center Program under a NIH grant; since 1994, he has served as an Adjunct Associate Professor of Tropical Medicine at the Tulane School of Public Health. An accomplished researcher and clinician, Dr. Doumbo has acted as primary investigator for numerous malarial drug trials, and worked on the WHO-sponsored Multilateral Initiative on Malaria/Special Programme for Research and Training in Tropical Diseases (MIM/TDR) task force on malaria research in Africa. Dr. Doumbo is the recipient of numerous scientific and teaching accolades, including the CIWARA PRICE in Biomedical Research, the Chevalier de l’Ordre National du Mali, the Chevalier de la Legion d’Honneur Francaise, and, most recently, the Research Award on Malaria in Africa at the 6ème Forum International in Bamako. Dr. Doumbo received his MD from the Faculty of Medicine, University of Mali and his PhD from the University of Montpellier, France in Parasitology. He has also received certificates in Epidemiology and Bioethics from Johns Hopkins and Harvard Universities.
Carlos Morel. MD, DSc. Director, Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation, Fiocruz; member, DNDi Board of Directors (Brazil)

Dr. Morel is the Director of CDTS and a Senior Researcher at the Oswaldo Cruz Foundation, an institution to which he has devoted thirty years of his distinguished career. He is a renowned expert on Chagas disease and a strong advocate for neglected disease research. Maintaining his affiliations with Fiocruz, he served from 1998 to 2004 as the Director of TDR (UNICEF-UNDP-World Bank-WHO Special Programme for Research and Training in Tropical Diseases). Prior to his work at Fiocruz, Dr. Morel was an Associate Professor with the Institute of Biology of the University of Brasilia, and earlier, an Assistant Professor with the University's Faculty of Medicine. Dr. Morel received his MD from the Federal University of Pernambuco (UFPE) and his DSc in Biophysics and Molecular Biology from the Federal University of Rio de Janeiro. Carlos is member of DNDi board of Directors since 2003.

William Lore, MD, MRCP, FRCP. Editor-in-Chief, The East African Medical Journal (Kenya)

William Lore studied medicine at the Makerere Medical School, Uganda in the 1960s, and has worked as a medical doctor in many countries including Kenya, Uganda, the United Kingdom and Sweden. He was the Founder Chair of the Ethics and Research Committee of the Kenyatta National Hospital in the mid 1980s; a member of the KEMRI Ethics Review Committee, and a member and Founder Chair of the Moi University Teaching Hospital Ethics and Research Committee. He has been a member of the Health Sciences Specialist Review Committee of the National Council of Science and Technology. He has served as an editor with the East African Medical Journal for thirty years and has been Editor-in-Chief of this esteemed general medical journal since 1995. Dr. Lore has written one book on health sciences, contributed chapters to many others, and has over 200 papers in peer reviewed journals; edited several text books and contributed chapters to books on internal medicine and cardiology. National Chair of Kenya Medical Association for two consecutive terms and, similarly, Chair of the Kenya Association of Physicians, Dr. Lore is now retired from mainstream academia but still teaches on part time basis at the School of Medicine, University of Nairobi. His pet subject is medical ethics.

Prof. Khirana Bhatt. MD, MRCP. Member, Scientific Advisory Committee, DNDi

Professor Bhatt is a graduate of the University of Nairobi where she did masters in Internal Medicine in 1978 and is interested in Tropical Medicine and Infectious Diseases. She did a diploma in tropical Medicine and Hygiene from Royal College of Physician in London in 1987 and thereafter masters in Clinical Tropical Diseases from London School of Tropical Medicine and Hygiene. She has been teaching in the Department of Clinical Medicine and Therapeutics of University of Nairobi since 1979. She is the Chair of Ethics and Research Committee of Kenya National Hospital (KNH) and University of Nairobi (UoN) and also a member of Ethics Committee of Kenya Medical Research Institute (KEMRI). She has published articles in peer-reviewed journals in the field of tropical diseases. Has research interest in Leishmaniasis, Malaria and HIV. She was awarded staff merit award by the University of Nairobi in 2001 in recognition of outstanding contribution towards Universities mission and in 2007 was awarded Elder of Burning Spear by His Excellency the President of Kenya for the work done in the prevention of Malaria and HIV in Kenya.